On October 2, 2018 Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, reported that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotech companies in the industry (Press release, Compass Therapeutics, OCT 2, 2018, View Source [SID1234529744]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Compass, which completed its $132 million Series A financing this year, is forging a new approach to identifying antibody drug candidates that engage all targets in the biologically complex human immune synapse. The company’s antibody discovery platform enables the rapid identification of therapeutic candidates that engage with a broad range of epitopes and its StitchMabs bispecific screening platform enables the empirical, high-throughput identification of novel synergistic combinations and bispecifics. To date, the company’s integrated R&D approach has generated therapeutic candidates for more than 30 targets in cancer, inflammation and autoimmune disease. More than 15 of them are now advancing through preclinical development.
"We’re honored that the editors of FierceBiotech have recognized Compass for our pioneering approach to antibody-based therapeutics," said Thomas Schuetz, M.D., Ph.D., the company’s co-founder and chief executive officer. "We believe our empirical, unbiased approach to drug discovery will lead to therapeutics with new mechanisms to modulate the human immune system."
The Fierce 15 celebrates the spirit of being "fierce"— championing innovation and creativity, even in the face of intense competition. Selection to the list is based on factors including the strength of a company’s technology, partnerships and venture backers and its competitive market position.